


26-May-03 12:11pm From: SIM MCBURNEY

4185881163

T-000 P.05/05 F-004



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 09/30/2000. OMB 0851-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)Applicant: John DupreApplication No.: 08/737,446Filed: January 10, 1997Entitled: Treatment of DiabetesLondon Health Sciences Centre, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____ Frame _____ or for which a copy thereof is attached

OR

B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below.

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee

May 26, 2003

Date

Joseph Gilbert
Signature

Dr. Joseph Gilbert

Typed or printed name

Vice President, Research & Innovation

Title

RECEIVED

JUN 13 2003

TECH CENTER 1600/2900

PATENT

ASSIGNMENT

Effective February 21, 2003, and for valuable consideration, we, Amylin Pharmaceuticals, Inc., a corporation organized and existing under and by the virtue of the laws of Delaware and having a place of business at 9373 Towne Centre Drive, San Diego, California 92121, and its successors and assigns; (hereinafter referred to as "Assignors") hereby assign to London Health Sciences Centre, an institution having offices, 375 South Street, London, Ontario N6A 4G5, CANADA, its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the invention and improvements which are the subject of the patents and patent applications listed below, and related applications and patents, any and all United States and foreign patents granted for any of said inventions or improvements, including all divisions, continuations, reissues, continuations-in-part and extensions thereof, and all causes of action for the patents and patent applications listed below, and the right to claim priority based on the filing date of said application and based on the filing date of any provisional application of which said application claims the benefit under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in its own name for patents and like rights of exclusion and for inventor's certificates for said inventions and improvements; and Assignee agrees for ourselves and our legal representatives and assigns, without further compensation, upon request to perform such lawful acts, to promptly provide Assignee with all pertinent facts and documents relating to said invention or application as may be known and accessible to us, to testify in any interference or litigation related to said invention or application and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this Assignment.


Docket No.	Country	Application No. Filing Date	Patent No. Issue/ Grant Date
223/051	U.S.	08/737,446 8 Nov 1996	
241/145	U.S.	09/280,020 29 Mar 1999	
223/051	Europe – Registered in: Austria, Belgium, Switzerland/ Liechtenstein, Germany, Denmark, Spain, France, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, and Sweden	95917874.0 12 May 1995	0762890 26 Jul 2000
223/051	Australia	24044/95 12 May 1995	711611 9 Aug 1999
223/051	Canada	2190112 12 May 1995	
223/051	Japan	529262/1995 12 May 1995	

PATENT

The Assignors hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Agreement.

WITNESS my hand at San Diego,
this 16th Day of April, 2003.

AMYLIN PHARMACEUTICALS, INC.



Lloyd A. Rowland
Vice President and General Counsel

STATE OF California)
) ss
COUNTY OF San Diego)

On April 16, 2003 before me, Cassandra Peters
Amanda J. Halverson, Notary Public, personally appeared
Lloyd A. Rowland

☒ personally known to me - OR - ☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.



Cassandra Peters
Notary Public in and for said County and State